Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4)

Production, characterization and immunogenicity

Xiaodong Xiao, Sanjay Phogat, Yuuei Shu, Adhuna Phogat, Yen Hung Chow, Olivia L. Wei, Harris Goldstein, Christopher C. Broder, Dimiter S. Dimitrov

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The ability to readily elicit broadly neutralizing antibodies to HIV-1 remains elusive. We and others have hypothesized that interaction of the viral envelope glycoprotein (Env, gp120-gp41) with its receptor molecules could enhance the exposure of conserved epitopes that may facilitate the elicitation of broadly neutralizing antibodies. The Env-CD4-coreceptor complexes mediate HIV-1 entry into cells and serve as a major target for inhibitors of this process. To begin to evaluate their potential also as vaccine immunogens we produced relatively large amounts of complexes of purified recombinant soluble truncated Env, gp14089.6 or gp12089.6, with CD4 and CCR5 or CXCR4. We found that gp140(gp120)-CD4-CCR5 complexes are stable and immunogenic in mice transgenic for human CD4 and CCR5. They elicited anti-gp120 and anti-gp140 antibodies that inhibited an heterologous primary HIV-1 isolate (JR-FL) with two- to threefold higher neutralizing activity than those elicited by gp120 and gp140. The antibodies elicited by the complexes competed better with the antibodies X5 and CG10 but not with b12 for binding to gp120 and gp120-CD4 complexes compared to those elicited with gp140(120) alone. These findings suggest that stable purified Env-CD4-CCR5(CXCR4) complexes can be produced in relatively large amount sufficient for their further characterization that may help in the development of novel vaccines candidates.

Original languageEnglish (US)
Pages (from-to)4275-4284
Number of pages10
JournalVaccine
Volume21
Issue number27-30
DOIs
StatePublished - Oct 1 2003

Fingerprint

Human immunodeficiency virus 1
HIV-1
glycoproteins
Glycoproteins
immune response
neutralizing antibodies
antibodies
Neutralizing Antibodies
vaccines
Vaccines
env Gene Products
neutralization
epitopes
Antibodies
genetically modified organisms
Transgenic Mice
antigens
Epitopes
Anti-Idiotypic Antibodies
receptors

Keywords

  • AIDS
  • CCR5
  • CD4
  • CXCR4
  • gp120
  • gp140
  • gp41
  • HIV

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Xiao, X., Phogat, S., Shu, Y., Phogat, A., Chow, Y. H., Wei, O. L., ... Dimitrov, D. S. (2003). Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): Production, characterization and immunogenicity. Vaccine, 21(27-30), 4275-4284. https://doi.org/10.1016/S0264-410X(03)00494-8

Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4) : Production, characterization and immunogenicity. / Xiao, Xiaodong; Phogat, Sanjay; Shu, Yuuei; Phogat, Adhuna; Chow, Yen Hung; Wei, Olivia L.; Goldstein, Harris; Broder, Christopher C.; Dimitrov, Dimiter S.

In: Vaccine, Vol. 21, No. 27-30, 01.10.2003, p. 4275-4284.

Research output: Contribution to journalArticle

Xiao, X, Phogat, S, Shu, Y, Phogat, A, Chow, YH, Wei, OL, Goldstein, H, Broder, CC & Dimitrov, DS 2003, 'Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): Production, characterization and immunogenicity', Vaccine, vol. 21, no. 27-30, pp. 4275-4284. https://doi.org/10.1016/S0264-410X(03)00494-8
Xiao, Xiaodong ; Phogat, Sanjay ; Shu, Yuuei ; Phogat, Adhuna ; Chow, Yen Hung ; Wei, Olivia L. ; Goldstein, Harris ; Broder, Christopher C. ; Dimitrov, Dimiter S. / Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4) : Production, characterization and immunogenicity. In: Vaccine. 2003 ; Vol. 21, No. 27-30. pp. 4275-4284.
@article{dc02dd504f1948ee857b1541fa2e6615,
title = "Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): Production, characterization and immunogenicity",
abstract = "The ability to readily elicit broadly neutralizing antibodies to HIV-1 remains elusive. We and others have hypothesized that interaction of the viral envelope glycoprotein (Env, gp120-gp41) with its receptor molecules could enhance the exposure of conserved epitopes that may facilitate the elicitation of broadly neutralizing antibodies. The Env-CD4-coreceptor complexes mediate HIV-1 entry into cells and serve as a major target for inhibitors of this process. To begin to evaluate their potential also as vaccine immunogens we produced relatively large amounts of complexes of purified recombinant soluble truncated Env, gp14089.6 or gp12089.6, with CD4 and CCR5 or CXCR4. We found that gp140(gp120)-CD4-CCR5 complexes are stable and immunogenic in mice transgenic for human CD4 and CCR5. They elicited anti-gp120 and anti-gp140 antibodies that inhibited an heterologous primary HIV-1 isolate (JR-FL) with two- to threefold higher neutralizing activity than those elicited by gp120 and gp140. The antibodies elicited by the complexes competed better with the antibodies X5 and CG10 but not with b12 for binding to gp120 and gp120-CD4 complexes compared to those elicited with gp140(120) alone. These findings suggest that stable purified Env-CD4-CCR5(CXCR4) complexes can be produced in relatively large amount sufficient for their further characterization that may help in the development of novel vaccines candidates.",
keywords = "AIDS, CCR5, CD4, CXCR4, gp120, gp140, gp41, HIV",
author = "Xiaodong Xiao and Sanjay Phogat and Yuuei Shu and Adhuna Phogat and Chow, {Yen Hung} and Wei, {Olivia L.} and Harris Goldstein and Broder, {Christopher C.} and Dimitrov, {Dimiter S.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0264-410X(03)00494-8",
language = "English (US)",
volume = "21",
pages = "4275--4284",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "27-30",

}

TY - JOUR

T1 - Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4)

T2 - Production, characterization and immunogenicity

AU - Xiao, Xiaodong

AU - Phogat, Sanjay

AU - Shu, Yuuei

AU - Phogat, Adhuna

AU - Chow, Yen Hung

AU - Wei, Olivia L.

AU - Goldstein, Harris

AU - Broder, Christopher C.

AU - Dimitrov, Dimiter S.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - The ability to readily elicit broadly neutralizing antibodies to HIV-1 remains elusive. We and others have hypothesized that interaction of the viral envelope glycoprotein (Env, gp120-gp41) with its receptor molecules could enhance the exposure of conserved epitopes that may facilitate the elicitation of broadly neutralizing antibodies. The Env-CD4-coreceptor complexes mediate HIV-1 entry into cells and serve as a major target for inhibitors of this process. To begin to evaluate their potential also as vaccine immunogens we produced relatively large amounts of complexes of purified recombinant soluble truncated Env, gp14089.6 or gp12089.6, with CD4 and CCR5 or CXCR4. We found that gp140(gp120)-CD4-CCR5 complexes are stable and immunogenic in mice transgenic for human CD4 and CCR5. They elicited anti-gp120 and anti-gp140 antibodies that inhibited an heterologous primary HIV-1 isolate (JR-FL) with two- to threefold higher neutralizing activity than those elicited by gp120 and gp140. The antibodies elicited by the complexes competed better with the antibodies X5 and CG10 but not with b12 for binding to gp120 and gp120-CD4 complexes compared to those elicited with gp140(120) alone. These findings suggest that stable purified Env-CD4-CCR5(CXCR4) complexes can be produced in relatively large amount sufficient for their further characterization that may help in the development of novel vaccines candidates.

AB - The ability to readily elicit broadly neutralizing antibodies to HIV-1 remains elusive. We and others have hypothesized that interaction of the viral envelope glycoprotein (Env, gp120-gp41) with its receptor molecules could enhance the exposure of conserved epitopes that may facilitate the elicitation of broadly neutralizing antibodies. The Env-CD4-coreceptor complexes mediate HIV-1 entry into cells and serve as a major target for inhibitors of this process. To begin to evaluate their potential also as vaccine immunogens we produced relatively large amounts of complexes of purified recombinant soluble truncated Env, gp14089.6 or gp12089.6, with CD4 and CCR5 or CXCR4. We found that gp140(gp120)-CD4-CCR5 complexes are stable and immunogenic in mice transgenic for human CD4 and CCR5. They elicited anti-gp120 and anti-gp140 antibodies that inhibited an heterologous primary HIV-1 isolate (JR-FL) with two- to threefold higher neutralizing activity than those elicited by gp120 and gp140. The antibodies elicited by the complexes competed better with the antibodies X5 and CG10 but not with b12 for binding to gp120 and gp120-CD4 complexes compared to those elicited with gp140(120) alone. These findings suggest that stable purified Env-CD4-CCR5(CXCR4) complexes can be produced in relatively large amount sufficient for their further characterization that may help in the development of novel vaccines candidates.

KW - AIDS

KW - CCR5

KW - CD4

KW - CXCR4

KW - gp120

KW - gp140

KW - gp41

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=0347448154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347448154&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(03)00494-8

DO - 10.1016/S0264-410X(03)00494-8

M3 - Article

VL - 21

SP - 4275

EP - 4284

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 27-30

ER -